The prevalence and determinants of catastrophic health expenditures attributable to non-communicable diseases in low- and middle-income countries: a methodological commentary by Goryakin, Yevgeniy & Suhrcke, Marc
Goryakin and Suhrcke International Journal for Equity in Health 2014, 13:107
http://www.equityhealthj.com/content/13/1/107RESEARCH Open AccessThe prevalence and determinants of
catastrophic health expenditures attributable
to non-communicable diseases in low- and
middle-income countries: a methodological
commentary
Yevgeniy Goryakin1,2* and Marc Suhrcke1,2,3Abstract
Background: Non-communicable diseases (NCDs), while traditionally considered a “rich world”-problem, have been
spreading fast in low and middle income countries and by now account for a large share of mortality and ill-health
in these countries, too. In addition to the disease burden, NCDs may also impose a substantial economic cost.
One way in which NCDs might impact people’s economic well-being may be via the out-of-pocket expenditures
required to cover treatment and other costs associated with suffering from an NCD.
Methods: In this commentary, we identify and discuss the methodological challenges related to cross-country
comparison of-out-of-pocket and catastrophic out-of-pocket health care expenditures, attributable to NCDs,
focussing on low and middle income countries.
Results: There is significant evidence of substantial cost burden placed by NCDs on patients living in low and
middle income countries, with most of it being heavily concentrated among low socioeconomic status groups.
However, a large variation in definition of COOPE between studies prevents cross-country comparison. In addition,
as most studies tend to be observational, causal inferences are often not possible. This is further complicated by the
cross-sectional nature of studies, small sample sizes, and/or limited duration of follow-up of patients. Most evidence
for certain conditions (e.g., cancer) tends to be collected in high-income countries only.
Conclusions: The definitions for COOPEs should be standardized as much as possible, to enable comparison of
COOPE prevalence between countries. Prospective study design using larger samples representative of broader
sections of local population, collecting better data on both direct and indirect treatment costs is also needed.
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Non-communicable diseases (NCDs), while traditionally
considered a “rich world”-problem, have been spreading
fast in low and middle income countries (LMICs) and by
now account for a large share of mortality and ill-health
in these countries, too [1,2]. In addition to the disease* Correspondence: y.goryakin@uea.ac.uk
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article, unless otherwise stated.burden, NCDs may also impose a substantial economic
cost. This is particularly likely in LMICs that lack appro-
priate health spending pre-payment systems, such as
health insurance [3]. When out-of-pocket medical care
expenditures are very large, relative to the material re-
sources available to the household, they may become
“catastrophic” [4].
In this paper we identify and discuss a series of meth-
odological challenges related to cross-country comparison
of out-of-pocket expenditures (OOPE) and catastrophicd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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utable to NCDs, focussing on LMICs. These challenges
have been identified on the basis of an extensive review of
the relevant literature, the details of which are available in
the Additional files 1 and 2.
Variable definition
Cross-country comparison of COOPE prevalence is greatly
complicated by the fact that the definition of COOPEs
varies between studies [5], although in at least one study,
prevalence was estimated in multiple countries using a
common definition [6].
The two main components in estimating COOPEs are
household-specific OOPEs, which enters the numerator,
and some measure of household resources, i.e. typically
income, consumption or spending [7], which enters the
denominator. The simplest approach is to use total in-
come in the denominator [8,9]. The problem with this
strategy is that it may lead to the underestimation of the
extent of COOPEs, as it does not take into account other
basic needs (e.g. food). Therefore, one widely used alterna-
tive approach is to define COOPEs as total out-of-pocket
expenditures on health as a proportion of total expendi-
tures or income, net of some commonly-defined poverty
line measure of resources, such as one dollar per day in-
come or spending [5]. However, as it does not take into
account location-specific costs to satisfy basic needs, it
may give a distorted picture of COOPEs prevalence in any
given country. To account for this, the denominator may
be alternatively defined as income or expenditures net of
essential spending, such as on food [5,7]. However, the
drawback of this approach is that it may compromise
cross-country comparisons, as the cost of essential items
may vary a great deal across locations.
Thresholds
Another complication is that COOPEs are often defined
in relation to a specific threshold (e.g., health expendi-
tures accounting for at least 20% of disposable income).
However, such thresholds often vary between studies,
and therefore cross-country comparisons may be diffi-
cult when non-standard thresholds are used. In practice,
lower thresholds (e.g., 10%) are typically used to define
COOPEs when total expenditures are in the denominator,
while considerably higher ones (e.g. 40%) are applied when
non-food expenditures are part of the denominator [7].
Income vs consumption
As the main purpose of estimating COOPE prevalence is
to study the effect of illness on living standards, using
income instead of consumption (e.g., proxied by expen-
ditures) in the denominator may not necessarily address
this purpose [7]. For example, the evidence suggests that
some households may be able to finance high OOPEs onhealth in a number of ways, e.g. by selling their assets or
utilizing their savings [6,10-12], by increasing their in-
come transfers [11], by accepting help from their extended
family or friends [6], or by some other measures such as
borrowing and access to microfinance [10,12-15]. This
may not be obvious if the denominator is defined by in-
come rather than spending [7].
Definition of OOPE
An additional complication is that the definition of out-
of-pocket expenditures may vary between studies, and
may [8,16-18] or may not [9,19,20] include spending on
indirect items such as cost of travel, employment-related
losses, or caretaker burden. As those cost elements are
usually not covered by health insurance, they may need
to be considered as part of OOPEs. Thus, some reviewed
studies found that earnings losses may be significantly
larger than medical OOPEs [7,18]. In Sri Lanka, it was
found that although public health system use is free at
the point of delivery and OOPEs on health care are mo-
dest [21], sometimes several direct and indirect costs
either prevent people from following diabetes treatment
regimens as prescribed, or expose them to greater risk of
economic hardship [16].
Even the definitions employed for direct costs vary sub-
stantially between studies, with some including expendi-
tures on tests and diagnostics and others not. In addition,
assumptions are sometimes made about the costs of drugs
and the patterns of their use, or on income level or fre-
quency of disease occurrence rather than on actual re-
cords [22,23]. Also, most metrics designed to estimate
prevalence of COOPE do not take into account house-
holds that may choose to forego medical treatment
altogether because it may be too expensive for them
[7,24]. An alternative definition to address this specific
complication is to measure exposure to, rather than the
actual payment of OOPE [7], although accurate collection
of such data may be very challenging.
Sampling issues
There is considerable heterogeneity between studies in
sample sizes, ranging from very small (e.g., 32 families
living in one country [8], or 34 patients with chronic
conditions- in another [25]), to much larger ones (121,051
individuals living in 35 countries [26], or 39,060 people
living in one country [9]). In some studies, sampling was
done on the household level [11,27], while in others (e.g.,
[17]) on the individual level.
Another serious sampling problem relates to self-
selection, or to sampling from unrepresentative groups.
While in some reviewed studies the samples are nation-
ally representative [9], this is not the case in many other
studies. For example, the selected sample is often re-
stricted to hospitalized patients only (e.g., [6,28]), or to
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may be deliberately oversampled (e.g., wealthier house-
holds [29]), which may complicate generalizing to other
population groups [30]. If, for instance, hospitalized pa-
tients are in worse health than the population at large,
then the population-level probability of incurring COOPE
may be overestimated. On the other hand, the cost esti-
mates for such patients may be under-estimated if their
costs in the community are not followed up upon their
discharge from hospital. Likewise, if hospitalization costs
are very high in some countries, and hence only wealthier
(and relatively healthier) people are likely to be admitted,
then again such results may be difficult to compare with
studies where such problems do not exist. In addition
there may be reporting bias, as patients tend to have diffi-
culty keeping track of their income/expenditure for an ex-
tended period of time [6].
Follow-up issues
Follow-up times do vary between studies and are com-
monly rather short (e.g. up to 12 months), potentially
limiting cross-country comparability as well as capturing
the long-term effect of NCDs [31]. Some conditions (e.g.
stroke) may require extended and costly rehabilitation
periods in the community [31], which are rarely followed
up in studies. LMICs in particular tend to lack longitu-
dinal data of sufficient duration [32], although some
studies have used panel datasets [11,15], or at least re-
peated cross-sectional design [33]. Expenditures on
some diseases (eg cancer) may also exhibit nonlinear
patterns. For example, health care expenditures tend to
be the highest in the first 6 months after diagnosis, and
12 months before death [34]. Therefore, the estimated
average costs may to a large extent depend on the over-
lap of the follow-up period with the course of the dis-
ease. Similarly, if average rather than actual costs of
drugs are analyzed, estimated OOPEs may be mislead-
ing, especially if drug prices fluctuate considerably.
Research design
A majority of studies simply report descriptive statistics
on how the risk of incurring COOPE varies by different
patient characteristics. Some studies assess the average
total cost of care among patients with a specified chro-
nic condition [19,22], generally in relation to the annual
or monthly income measure [17], while some others
provide mean values of OOPE/COOPE, without res-
tricting the sample to chronic patients [10], or without
any comparison in these outcomes between patients
with and without chronic illnesses [16]. This may lead
to an overestimate of the NCD-attributable expendi-
tures, although some studies do have a reference group,
or at least a random population sample [35] for
comparison.To account for the possibility that OOPEs may differ
between patients for reasons other than having a chronic
illness, some studies examine the correlation between
having a chronic disease and OOPE while also control-
ling for several potential (mostly socioeconomic, demo-
graphic and health) confounders [11,26,32]. However, this
is not standard practice, which makes cross-country-
comparison of results more difficult.
Overall, the cross-sectional design is most frequently
employed in this literature – a feature that tends to limit
causal inference, as important unobservable determi-
nants may be located at the individual level, which
country fixed effects and existing controls cannot
account for [26].
Although one author did take advantage of the longi-
tudinal nature of the data and employed instrumental
variable estimators to control for potential endogeneity
of chronic disease indicators [11], the choice of the in-
struments did not appear to be fully justified.
Other issues regarding cross-country comparisons
A number of other issues have also been found to poten-
tially affect cross-country comparisons of prevalence and
determinants of NCD-related COOPE. Thus, in many
cases, self-reported information on diseases and condi-
tions is used, rather than actual diagnosis [11,26,32,36].
For example, measured information on fasting blood glu-
cose is often unavailable, and the diagnosis is therefore
self-reported, although usually based on prior diagnosis
(which may depend on access to health services). Simi-
larly, the use of self-reported medical spending may be
subject to recall bias, or to over- or under-reporting re-
lated to socioeconomic status (SES).
The patient mix is also often difficult to compare. For
example, in some studies, patients with both chronic
and non-chronic disease have been included, without a
clear distinction [17,29]. Similarly, some authors (e.g.
[13,14]) looked at the effect of changes in ability to per-
form various activities of daily living (ADL) on medical
spending, which they argue are important proxies for
physical functioning ability. However, it is not clear to
what extent such changes are due to NCDs rather than
communicable or other conditions.
Estimating prevalence of COOPE is further compli-
cated by the fact that in some countries, average OOPEs
may be relatively low not because the treatments are
cheap, but because they are estimated conditional on re-
ceiving treatment. If they are perceived as unaffordable
by a large proportion of the population, and these costs
are therefore not incurred [6,8,36], an erroneous conclu-
sion may be drawn that COOPE prevalence is low.
We also found that the strength of the relationship be-
tween having a disease and incurring COOPE may vary
not only by disease, but also by national income level
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between countries at different levels of economic devel-
opment. The magnitude (as opposed to prevalence) of
COOPE may also differ depending on the national level of
income, which is difficult to capture if a threshold-based
measure of COOPEs (e.g., 30% of expenditures accounted
for by OOPE) is used. For example, in one of the poorest
countries in the world – Tajikistan – one episode of hos-
pital stay could cost as much as patients’ total annual in-
come [10], with about 70% of the poorest quintile reporting
that patients did not buy drugs even though they had a
medical prescription, because they could not afford to.
Finally, some studies have attempted to measure
SES-related inequalities in the prevalence of COOPE
[6,8,19,31,36-40], and generally found that those with
the least income/education, or living in the poorest coun-
tries are most likely to incur large OOPE [6,8,19,31,36,37],
and that when health care is consumed, financial burden
appears to concentrate heavily among patients in lower
SES status [9,10,18,20,23,33,36,41]. Nevertheless, despite
the existence of standard approaches for measuring
COOPE-related inequalities [7], including indirect and
direct standardization methods, very few if any studies
utilize them.
Conclusions
In this paper we have provided – based on an in depth
review of the relevant evidence base – a discussion of
the methodological challenges facing researchers who
are interested in comparing prevalence and determinants
of NCD-related COOPEs across countries.
It is important to emphasize that while another recent
systematic review [42] considered financial burden from
non-communicable diseases in LMICs, our commentary
is different in two important respects. First, we are much
more focussed on COOPE (as opposed to “financial
burden”) than Kankeu et al [42]. Second, we dedicate
a particularly significant share of the discussion on
methodological issues and challenges in these studies.
It is also important to be mindful of the limitations of
our discussion, and in particular of the underlying re-
view. Thus, we cannot exclude the possibility that we
may have overlooked some relevant evidence, especially
in the non-English literature. Furthermore, although we
tried to review as broad a selection of articles as pos-
sible, our review was not truly systematic, and may
therefore have overlooked some relevant articles. Never-
theless, the sample of studies that we did find may be
expected to cover the predominant part of the relevant
body of work in this field, and our discussion suggests a
number of lessons for future research:
First, if the goal is to facilitate comparisons of COOPE
prevalence between countries, the definitions for both
numerator and denominator, as well as the threshold levelat which OOPEs become catastrophic, should be stan-
dardized as much as possible. The comparisons should
ideally be based on the common length of the follow-up
period, as well as on common disease definitions, prefera-
bly determined by clinical assessment.
Second, our study has confirmed the existence of a
significant socioeconomic gradient in the prevalence of
chronic disease-related COOPE in developing countries.
Given the important equity implications of this finding,
greater effort should be directed at more uniform meas-
urement of such gradient across countries. For example,
the direct or indirect standardization for age and gender
and the use of concentration indices, may facilitate cross-
country comparisons of socioeconomic inequalities across
countries.
Third, comparisons will also be facilitated by using
similar sampling frames (preferably not restricted to
hospitalized patients only), and appropriate designs to
elicit sufficient response rates.
Fourth, to evaluate the true extent of COOPE, better
data on indirect costs should be collected. This is espe-
cially true for countries with more generous health in-
surance systems, where direct costs may be covered well,
as well as for very low-income countries, where cost com-
ponents such as travel costs may be prohibitive.
Fifth, more reliable data on medication costs and their
use should be collected in LMICs, given their import-
ance in OOPE.
Sixth, prospective data collection is preferred to avoid
recall bias problems. In addition, real rather than esti-
mated or assumed cost/utilisation data should be used.
Finally, more studies should be conducted to address the
potential problems of the endogeneity of chronic illness.
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